Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ASPI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Related Party (new) — The merger involves ASPI's wholly-owned subsidiary Noble Africa in a related-party transaction structure, with ASPI directors and management investing $750K in the concurrent private placement.
ASP Isotopes to spin off Renergen holding via ENDRA merger, secures $50M financing
Filed June 25, 2026 · Period ending June 25, 2026 · ~1 min read
Key Changes
-
high
ASPI's wholly-owned subsidiary Noble Africa (holding Renergen Limited) will merge with an ENDRA Life Sciences subsidiary, with Noble Africa surviving and listing on Nasdaq as NOBA; ASPI to retain ~89% ownership post-close.
Item 7.01 — Regulation FD Disclosure verify on EDGAR → -
high
Noble Africa secured $50M private placement commitments, with ASPI investing $20M as lead investor and other investors (including $750K from ASPI directors/management) contributing $30M; financing closes immediately before merger.
Item 7.01 — Regulation FD Disclosure verify on EDGAR → -
medium
Both boards approved the transaction, expected to close Q3-Q4 2026 subject to SEC registration effectiveness, ENDRA stockholder approval, and customary conditions.
Item 7.01 — Regulation FD Disclosure verify on EDGAR → -
medium
Combined company will be led by Paul E. Mann (CEO) and Nick Mitchell (COO), with a six-member board: CEO plus four non-executive directors from ASPI and one from ENDRA.
Item 7.01 — Regulation FD Disclosure verify on EDGAR →
Summary
ASP Isotopes announced a proposed merger that will effectively spin off its Renergen Limited holding into a separately traded public company. The transaction merges Noble Africa, ASPI's wholly-owned subsidiary that holds Renergen, with an ENDRA Life Sciences subsidiary.
Noble Africa will survive the merger and list on Nasdaq under ticker NOBA, with ASPI retaining approximately 89% ownership, ENDRA stockholders receiving approximately 3%, and new private placement investors holding approximately 7%. The structure includes a concurrent $50 million private placement into Noble Africa, with ASPI committing $20 million as lead investor.
Notably, ASPI directors and management are investing $750,000 of the $30 million coming from other investors, creating a related-party dynamic that warrants attention. The transaction requires ENDRA stockholder approval and SEC registration statement effectiveness, with closing expected in Q3 or Q4 2026. For ASPI shareholders, this represents a significant corporate restructuring that maintains majority control of Renergen's Virginia Gas Project while bringing in external capital and creating a separately traded vehicle. The related-party aspects—both the subsidiary merger structure and insider participation in the financing—merit scrutiny of the terms and fairness opinions when the registration statement is filed.
Section-by-Section Diff
Event · Exhibit 99.1
ASP Isotopes announces proposed merger of subsidiary Noble Africa with ENDRA Life Sciences and concurrent $50M private placement financing.
Added in current filing · view on EDGAR →
ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes," “ASPI” or the "Company"), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, and ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or “NDRA”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that ASP Isotopes’ wholly-owned subsidiary, Noble Africa LLC (“Noble Africa”), an intermediate holding company for Renergen Limited (“Renergen”), will merge with a subsidiary of ENDRA, with Noble Africa continuing as the surviving entity (the “Proposed Merger” and, together with the related transactions, the “Proposed Transactions”). Upon completion of the Proposed Transactions, the combined company plans to operate under the name Noble Africa Inc. and will apply to trade on The Nasdaq Stock Market LLC (“Nasdaq”) under the ticker symbol “NOBA.”
ASP Isotopes disclosed a proposed merger where its wholly-owned subsidiary Noble Africa (which holds Renergen Limited) will merge with a subsidiary of ENDRA Life Sciences. Noble Africa will be the surviving entity and plans to list on Nasdaq under ticker NOBA. The transaction is designed to establish Noble Africa as a publicly traded helium platform for Renergen's Virginia Gas Project. Upon closing, ASP Isotopes is expected to own approximately 89% of the combined company, pre-closing ENDRA stockholders approximately 3%, and private placement investors approximately 7%.
Added in current filing · view on EDGAR →
The combined company plans to operate under the name Noble Africa Inc. and will initially be led by Paul E. Mann, Chief Executive Officer of Renergen and Chief Executive Officer and Executive Chairman of ASP Isotopes, and Nick Mitchell, Chief Operating Officer of Renergen and Co-Chief Operating Officer of ASP Isotopes. The combined company’s Board of Directors will consist of six directors selected by ASP Isotopes, including the Chief Executive Officer of the combined company, four non-executive directors designated by ASP Isotopes and one non-executive director designated by ENDRA.
The combined company will be named Noble Africa Inc. and led by Paul E. Mann as CEO and Nick Mitchell as a key operating executive. The board will have six directors: the CEO plus four non-executive directors designated by ASP Isotopes and one non-executive director designated by ENDRA. This governance structure reflects ASP Isotopes' controlling ownership stake in the combined entity.
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
the proposed merger of Noble Africa LLC (“Noble Africa”), a wholly-owned subsidiary of the Company and an intermediate holding company for Renergen Limited, with a subsidiary of ENDRA, with Noble Africa continuing as the surviving entity
ASPI disclosed a proposed merger where Noble Africa, its wholly-owned subsidiary that holds Renergen Limited, will merge with a subsidiary of ENDRA Life Sciences Inc. Noble Africa will be the surviving entity after the merger. This transaction restructures ASPI's ownership of Renergen through a combination with ENDRA.
Added in current filing · verify on EDGAR →
Noble Africa has entered into subscription agreements with certain accredited investors, qualified institutional buyers and non U.S.-persons securing commitments for a private placement into Noble Africa that is expected to result in total gross proceeds of approximately $50 million
Noble Africa secured commitments for a $50 million private placement from accredited investors, qualified institutional buyers, and non-U.S. persons. This financing is being raised into Noble Africa, the entity that will survive the merger with ENDRA's subsidiary, providing significant capital to the combined structure.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 25, 2026 · How we verify